V
Vishal Verma
Researcher at Genentech
Publications - 56
Citations - 2208
Vishal Verma is an academic researcher from Genentech. The author has contributed to research in topics: Bryostatin & Nucleoside. The author has an hindex of 20, co-authored 55 publications receiving 1980 citations. Previous affiliations of Vishal Verma include Merck & Co. & Stanford University.
Papers
More filters
Journal ArticleDOI
Function-oriented synthesis, step economy, and drug design.
TL;DR: Improved transporters that can deliver agents in a superior fashion compared with naturally occurring cell-penetrating peptides and that can be synthesized in a practical and step-economical fashion are generated.
Journal ArticleDOI
Structural basis for dual-mode inhibition of the ABC transporter MsbA
Hoangdung Ho,Anh Miu,Mary Kate Alexander,Natalie K. Garcia,Angela Oh,Inna Zilberleyb,Mike Reichelt,Cary D. Austin,Christine Tam,Stephanie Shriver,Huiyong Hu,Sharada Labadie,Jun Liang,Lan Wang,Jian Wang,Yan Lu,Hans E. Purkey,John G. Quinn,Yvonne Franke,Kevin R Clark,Maureen Beresini,Man-Wah Tan,Benjamin D. Sellers,Till Maurer,Michael F. T. Koehler,Aaron T. Wecksler,James R. Kiefer,Vishal Verma,Yiming Xu,Mireille Nishiyama,Jian Payandeh,Christopher M. Koth +31 more
TL;DR: A framework for the selective modulation of ABC transporters is established and provides rational avenues for the design of new antibiotics and other therapeutics targeting this protein family.
Journal ArticleDOI
Pharmacological inhibition of fatty acid synthase (FAS): a novel therapeutic approach for breast cancer chemoprevention through its ability to suppress Her-2/neu (erbB-2) oncogene-induced malignant transformation.
TL;DR: Interestingly, the degree of Her‐2/neu oncogene expression in a panel of breast cancer cell lines was predictive of sensitivity to chemical FAS inhibitors‐induced cytotoxicity, while low‐FAS expressing and chemical Fas inhibitors‐resistant MDA‐MB‐231 breast cancer cells became hypersensitive to FAS blockade.
Journal ArticleDOI
Design, synthesis, and evaluation of potent bryostatin analogs that modulate PKC translocation selectivity
Paul A. Wender,Jeremy L. Baryza,Stacey E. Brenner,Brian A. DeChristopher,Brian Loy,Adam J. Schrier,Vishal Verma +6 more
TL;DR: This study illustrates the application of function-oriented synthesis to the design and synthesis of functional analogs of the bryostatin marine natural products, specifically directed at exploring the activity-determining role of brystatin A-ring functionality on PKC affinity and selectivity.
Journal ArticleDOI
Actin is the primary cellular receptor of bistramide A
Alexander V. Statsuk,Ruoli Bai,Jeremy L. Baryza,Vishal Verma,Ernest Hamel,Paul A. Wender,Sergey A. Kozmin +6 more
TL;DR: Activity provides a molecular explanation for the potent antiproliferative effects of bistramide A, identifying it as a new biochemical tool for studies of the actin cytoskeleton and as a potential lead for development of a new class of antitumor agents.